Canopy Growth's mixed results stop momentum from recent marijuana-stock rally

Dow Jones
07 Feb

MW Canopy Growth's mixed results stop momentum from recent marijuana-stock rally

By Steve Gelsi

Canadian pot company posts another quarterly loss as adult-use sales slump, despite some bright spots

Canopy Growth Corp.'s stock fell sharply in premarket trading as the Canadian pot company's wider-than-expected third-quarter loss chilled a recent rally in its share price.

While Canopy Growth $(CGC.AU)$ managed to reduce its losses and pay down debt, its operating margins fell as it invested in a new product launch. It also faced weaker adult-use sales, although its medical-pot business grew.

Canopy Growth's stock fell 15% in premarket trading, after rising nearly 40% in the past week.

Canopy Growth said its third-quarter loss narrowed to C$121.9 million ($85 million), or C$1.11 a share, from a loss of C$216.8 million or C$2.62 a share, in the year-ago period.

Analysts had expected Canopy Growth to post a narrower loss of 52 cents a share.

Revenue fell 5% to C$74.76 million, ahead of the FactSet consensus estimate of C$69.1 million.

Adult-use sales fell 10% to C$21.2 million, while medical-cannabis sales jumped 16% to C$19.6 million.

Third-quarter gross margin fell by 4% to 32% from the year-ago level. Canopy Growth cited incremental costs related to the launch of its Claybourne-infused pre-rolls, as well as higher indirect costs at its Storz & Bickel vaporizer unit.

Canopy Growth also reduced its third-quarter debt to C$442 million from the previous quarter's debt of $C554 million by making an early prepayment on its senior secured term loan.

Fresh speculation about U.S. federal reforms for pot, as well as a rally in fellow Canadian pot company Aurora Cannabis Inc. $(ACB)$ (CA:ACB) fed gains in cannabis stocks earlier this week

Also read: Cannabis stocks extend gains on RFK Jr. committee vote, Senate banking comments

-Steve Gelsi

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

February 07, 2025 08:15 ET (13:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10